Gateway Investment Advisers LLC Sells 7,173 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Gateway Investment Advisers LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 69,654 shares of the biopharmaceutical company's stock after selling 7,173 shares during the period. Gateway Investment Advisers LLC's holdings in Gilead Sciences were worth $6,434,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Avior Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 1.2% in the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock worth $782,000 after buying an additional 108 shares during the period. Concord Asset Management LLC VA grew its stake in Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock valued at $256,000 after buying an additional 111 shares during the last quarter. TFB Advisors LLC lifted its position in shares of Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock worth $788,000 after purchasing an additional 116 shares during the last quarter. Sumitomo Life Insurance Co. grew its holdings in Gilead Sciences by 0.7% in the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company's stock valued at $1,494,000 after buying an additional 117 shares during the last quarter. Finally, FDx Advisors Inc. increased its position in Gilead Sciences by 2.2% in the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company's stock worth $450,000 after buying an additional 117 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 in the last 90 days. Insiders own 0.29% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. Leerink Partnrs raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Bank of America restated a "buy" rating and issued a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Robert W. Baird increased their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. Citigroup started coverage on Gilead Sciences in a report on Thursday, November 14th. They set a "buy" rating and a $125.00 target price on the stock. Finally, Oppenheimer raised their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $97.96.

Gilead Sciences Stock Performance

GILD traded up $0.19 during trading on Friday, hitting $91.84. The stock had a trading volume of 6,852,085 shares, compared to its average volume of 6,737,253. The company has a 50 day moving average price of $91.85 and a 200-day moving average price of $83.81. The firm has a market cap of $114.46 billion, a price-to-earnings ratio of 1,020.44, a P/E/G ratio of 1.27 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period last year, the company earned $2.29 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.35%. Gilead Sciences's payout ratio is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.